KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Invested Capital (2018 - 2025)

Historic Invested Capital for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $437.8 million.

  • Aurinia Pharmaceuticals' Invested Capital fell 662.79% to $437.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $437.8 million, marking a year-over-year decrease of 662.79%. This contributed to the annual value of $450.1 million for FY2024, which is 384.06% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Invested Capital of $437.8 million as of Q3 2025, which was down 662.79% from $410.8 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Invested Capital's 5-year high stood at $485.7 million during Q2 2023, with a 5-year trough of $298.2 million in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $437.8 million (2025), whereas its average is $425.0 million.
  • The largest annual percentage gain for Aurinia Pharmaceuticals' Invested Capital in the last 5 years was 4200.7% (2022), contrasted with its biggest fall of 1537.41% (2022).
  • Aurinia Pharmaceuticals' Invested Capital (Quarter) stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then rose by 15.44% to $468.1 million in 2023, then fell by 3.84% to $450.1 million in 2024, then dropped by 2.73% to $437.8 million in 2025.
  • Its last three reported values are $437.8 million in Q3 2025, $410.8 million for Q2 2025, and $421.5 million during Q1 2025.